SpyGlass Pharma, Inc. (SGP) (CIK 0001778922) (SGP)
Activity window: Oct. 25, 2025 to Oct. 24, 2026
Export this company’s current score, component values, matched signals, and scoring date as a one-row CSV snapshot.
The total combines correspondence volume, AI sentiment, matched keywords and signals, and a weighted 8-K adjustment, capped at 10.0. This is the 365-day v1 snapshot. Computed: Oct. 24, 2026. Latest filing activity: Jan. 29, 2026. These dates describe different events.
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Jan. 29, 2026 | CORRESP | Neutral/Informational | Moderate | SpyGlass Pharma, Inc. has submitted a correspondence to the SEC in response to comments received regarding their Registration Statement on Form S-1. The letter outlines the revisi… | Read Filing EDGAR |
| Jan. 29, 2026 | CORRESP | Neutral/Informational | Moderate | SpyGlass Pharma, Inc. has submitted a request to the SEC for the acceleration of their Registration Statement on Form S-1, seeking to have it declared effective on January 30, 202… | Read Filing EDGAR |
| Jan. 29, 2026 | CORRESP | Neutral/Informational | Moderate | SpyGlass Pharma, Inc. has submitted a request for the acceleration of the effectiveness of its Registration Statement on Form S-1, seeking to have it declared effective on January… | Read Filing EDGAR |
| Jan. 27, 2026 | UPLOAD | Concern from SEC | Moderate | The SEC has reviewed SpyGlass Pharma, Inc.'s registration statement on Form S-1 filed on January 16, 2026, and has issued a comment requiring clarification regarding the company's… | Read Filing EDGAR |
| Jan. 16, 2026 | CORRESP | Neutral/Informational | Moderate | SpyGlass Pharma, Inc. has submitted a response to comments from the SEC regarding their Draft Registration Statement on Form S-1. The correspondence details revisions made to the … | Read Filing EDGAR |
| Jan. 13, 2026 | UPLOAD | Concern from SEC | High | The SEC has reviewed SpyGlass Pharma, Inc.'s amended registration statement and issued comments requiring further clarification and sourcing for certain statements made in the fil… | Read Filing EDGAR |
| Dec. 1, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed SpyGlass Pharma, Inc.'s draft registration statement and provided a series of comments that require the company to clarify and amend various disclosures. Key … | Read Filing EDGAR |